Avacta Group PLC (LON:AVCT) reported interim results to January 2019, confirming good progress on key development programmes Lead immune checkpoint inhibitor programmes continue to move towards in-man clinical data in 2020 Major development partnership and licence agreement with LG Chem potentially w
09 Apr 2019
Avacta - interim results confirm progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Avacta - interim results confirm progress
Avacta Group PLC (AVCT:LON) | 45.5 0.5 2.2% | Mkt Cap: 163.4m
- Published:
09 Apr 2019 -
Author:
Ed Stacey -
Pages:
4
Avacta Group PLC (LON:AVCT) reported interim results to January 2019, confirming good progress on key development programmes Lead immune checkpoint inhibitor programmes continue to move towards in-man clinical data in 2020 Major development partnership and licence agreement with LG Chem potentially w